TRANSPARENCY

At Alnylam, we strongly believe that interactions with Health Care Providers (HCPs) and Healthcare Organizations (HCOs) positively influence the quality of patient treatment and the value of medical research. We are also fully committed to increased transparency within the pharmaceutical industry and to strengthening the public trust in the relationships between pharmaceutical companies and HCPs and HCOs.

We believe healthcare professionals; other relevant decision makers and healthcare organizations should be fairly compensated for the legitimate expertise and services they provide. Alnylam voluntarily discloses Transfers of Value to HCPs and HCOs in accordance with the EFPIA Code of Practice and the relevant local codes of practice and/or local legal requirements, and in accordance with all applicable data protection laws and regulations.

Below are the reports and methodological notes for each country publishing data in accordance with the EFPIA Code of Practice and other relevant local codes.